Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00696787 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT00696787 is a Phase 2 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 125 participants.
The verdict
NCT00696787, a Phase 2 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if DVS SR is safe and effective in the treatment of pain associated with fibromyalgia syndrome, and if so to identify the efficacious doses.
Interventions
- DRUG Placebo
- DRUG Desvenlafaxine Sustained Release (DVS SR)
- DRUG Lyrica® (Pregabalin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00696787
The ClinicalTrials.gov registry entry for NCT00696787 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00696787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00696787 about?
NCT00696787 is a clinical study titled "A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia". The purpose of this study is to evaluate if DVS SR is safe and effective in the treatment of pain associated with fibromyalgia syndrome, and if so to identify the efficacious doses.
What is the current status of trial NCT00696787?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2008-06. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00696787?
The interventions under investigation include: Placebo (DRUG), Desvenlafaxine Sustained Release (DVS SR) (DRUG), Lyrica® (Pregabalin) (DRUG).
Who is sponsoring clinical trial NCT00696787?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.